21.20.0
Производство фармацевтических препаратов
152
Общество с ограниченной или дополнительной ответственностью
03877
Агентство по развитию фармацевтической отрасли при Министерстве здравоохранения Республики Узбекистан
1718401
Республика Узбекистан, Самаркандская область, Самарканд
Stability rating:
Tax debt:
Is a large taxpayer:
Has a license:
Abuses the right to reduce VAT payable:
Is a resident of the IT Park:
Rating of participants in the electronic public procurement system:
Developer rating:
Included in the unified register of unscrupulous performers:
No data on arbitration cases
Information found about participation in government procurement as a supplier or customer
Supplier
119
Customer
0
Коротко о компании
IMKONPLUS PHARM has been operating since 2020 in the Производство фармацевтических препаратов industry. The director is Baxriddinov Muxammad-yusuf Baxodir O‘g‘li. The company belongs to the Small business category. Its primary activity is Производство фармацевтических препаратов. The company has 1 from $count_of_founders from other countries, one of whom owns a 100% stake. $count_of_licensing_text. The company has no registered property., $register_text, and 30 similar companies, indicating a highly competitive market.
Stability rating:
Tax debt:
Is a large taxpayer:
Has a license:
Abuses the right to reduce VAT payable:
Is a resident of the IT Park:
Rating of participants in the electronic public procurement system:
Developer rating:
Included in the unified register of unscrupulous performers:
3
0
3
0
No data on real estate
Коротко о компании
IMKONPLUS PHARM has been operating since 2020 in the Производство фармацевтических препаратов industry. The director is Baxriddinov Muxammad-yusuf Baxodir O‘g‘li. The company belongs to the Small business category. Its primary activity is Производство фармацевтических препаратов. The company has 1 from $count_of_founders from other countries, one of whom owns a 100% stake. $count_of_licensing_text. The company has no registered property., $register_text, and 30 similar companies, indicating a highly competitive market.